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Significant advances have been made during the last decade in asthma treatment, but concerns have 
been raised about the validity of trial results with respect to the entire asthma population, given the 
considerable heterogeneity of asthma sub-groups and short time duration of trials (1, 2). A basic 
reason for questioning general applicability of asthma therapeutics, is that participants of randomized 
controlled trials (RCTs) often represent only 5% of the asthma population due to strict trial eligibility 
criteria (3). Since the risk-benefit profile of new drugs can be unpredictable for the majority of asthma 
patients, we need to re-examine the issue of external validity of RCT results.  
 
Several groups of asthmatics are under-represented in RCTs. Patients prone to small airway disease 
such as those with refractory asthma, nocturnal asthma, exercise-induced asthma, smokers and those 
with co-existing allergic rhinitis (4) are often excluded from trials. Yet, these groups are likely to 
show a different response to inhaled corticosteroid treatment depending on the particle size of 
formulation (5). Despite the fact that patients with uncontrolled asthma can develop fixed airway 
obstruction, irreversible bronchoconstriction is often set as an exclusion criterion and disqualifies 
approximately 75% of asthma trial participants (3). In addition, patients with a smoking history of 
more than 10 pack-years are often excluded, even though it has been estimated that one out of four 
asthmatics in Europe are smokers (6), and smoking is associated with impaired therapeutic response 
to corticosteroids. Moreover, although significant comorbidity is present in roughly one third of 
asthmatics, more than half of RCTs exclude comorbidities (7, 8). If all the above mentioned asthma 
groups are excluded from RCTs it is very likely to result in uncertainty on the use of drugs in real-life 
clinical settings. 
 
It is, therefore, clear that development of alternative trial design approaches should be pursued, 
addressing the incorporation of external validity. This way we could avoid the debatable approval of 
drugs that apply to a small proportion of asthma patients and address the currently seeming 
unavoidable efficacy-effectiveness gap (9).  
To establish high external validity of trials as a requirement for drug approval, generalizability needs 
to be quantified in an objective manner. A useful tool to assess this could be the Pragmatic-
Explanatory Continuum Indicator (PRECIS-2) (10). This tool was originally created to assist trial 
design; nevertheless, it can also be used for critical assessment since it evaluates the eligibility 
criteria, recruitment process, trial setting, resources and expertise needed for the treatment, flexibility 
and adherence of treatment, follow-up of patients, relevancy of outcomes and extent of analysis. The 
parts of a trial design that relate to applicability are evaluated on a numeric scale, making it an 
objective and reproducible way to assess generalizability of trials.  
More specifically, we propose that external validity could be facilitated by a specific adaptive trial 
design composed of three phases [Fig1]. An initial exploratory phase would be characterized by strict 
eligibility criteria, controlled settings and follow-up in order to study the PK-PD relationship and 
determine the proposed dose. In a subsequent explanatory phase, the efficacy and safety of the drug 
would initially be assessed in a controlled and tightly defined patient population so that efficacy can 
be demonstrated. After confirmation of the risk/benefit profile, the study population will be enhanced, 
at an interim point. Population enhancement can be performed in two ways, either by broadening 
eligibility criteria of the pre-existing arms or by adding additional arms with broader eligibility 
criteria. The second method, would enable the parallel study of efficacy-safety in highly selected 
populations and in real world patients, generating data with both high internal and external validity at 
the same time, enabling greater generalizability of results and precision in patient subgroups.  
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We conclude that regulatory authorities need to request the submission of confirmatory data that 
demonstrates the generalizability and predictability of results to the whole patient population for 
whom the drug will finally be prescribed. Moreover, we propose to integrate external validity to 
RCTs of asthma drugs by developing novel trials characterized by an adaptive trial design and 
population enhancement at an interim point.  
 
Figures: 
Fig. 1: Trial design incorporating external validity. 
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